Skip to main content

pH-Responsive Nanoparticles Based on Covalently Grafted Conjugates of Carboxymethyl Chitosan and Daunorubicin for the Delivery of Anti-Cancer Drugs

Buy Article:

$107.14 + tax (Refund Policy)

The drug controlled release responding to tumour microenvironment is a hotspot for cancer therapy research. Herein, pH-sensitive shell-core nanoparticles (NPs) were devised and fabricated for tumour treatment. The detailed characterisations of their structures demonstrated the successful formation of the precursors and NPs. More importantly, the NPs show excellent features, i.e., negative surface potential, narrow size distribution, and suitable dimension for cell penetration. And they have superior stability in pH 7.4 buffer (i.e., blood environment). In addition, owing to the existence of the pH-labile imine bond, a controlled release of drugs from NPs was achieved in drug release test. Confocal laser scanning microscopy (CLSM) and flow cytometry proved the internalization of NPs into HeLa cells and their further translocation into cell nuclei. The cytotoxicity results also revealed a remarkable cytotoxicity of the NPs to HeLa cells. Thus, this type of NP may be potentially useful for the efficient drug delivery.

Keywords: CARBOXYMETHYL CHITOSAN; DAUNORUBICIN; INTERNALIZATION; NANOPARTICLES; PH-SENSITIVE

Document Type: Research Article

Publication date: 01 December 2017

More about this publication?
  • Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content